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Neurocognitive Markers of Suicidal Ideation in Patients with Anxiety and 
Mood Disorders 
Abstract 
Objective: This study aims at identifying associations between cognitive function and suicidal 
ideation in the sample of patients with anxiety and mood disorders (AMD). 
Methods: In sum, 186 (age = 39 ± 12.3 years; 142 [76.3 %] females) patients with AMD were 
enrolled in the study. Assessment included evaluation of socio-demographic information, 
medication use, anxiety and depression symptoms. Cognitive tests included measures of 
psychomotor performance and incidental learning using the Digit Symbol Test. Trail Making 
Tests respectively measured perceptual speed, task-switching and executive control. 
Additionally, 21 patients completed tests from the Cambridge Automated Neuropsychological 
Test Battery measuring set shifting (Interdimensional/extradimensional set-shift), executive 
planning (Stockings of Cambridge), and decision making (Cambridge Gamble Task [CGT]).  
Results: Almost half (45.0%, n = 86) of the study sample patients had experienced suicidal 
ideations. In multivariable regression analysis, suicidal ideation was associated with a greater 
overall proportion of bet and risk taking on the CGT task (β = .726, p = .010 and β = .634, p = 
.019), when controlling for socio-demographic characteristics, medication use, anxiety and 
depression symptoms. 
Conclusions: Outpatients with AMD and suicidal ideation could be distinguished by the 
presence of cognitive deficits in the executive function domain, particularly in impulse-control 
and risk taking. 
Keywords: suicidal ideation, neurocognitive markers, anxiety and mood disorders. 
  
Background 
Patients with anxiety and mood disorders (AMD) frequently experience suicidal ideation in the 
week prior to attempting suicide (Nock, Hwang, Sampson, & Kessler, 2010). Patients with 
AMD also show cognitive deficits, with impairments in executive functioning domains being 
the most prominent (Pu, Setoyama, & Noda, 2017). Recent studies have focused on finding 
factors that differentiate those who think about suicide from those who make a suicide attempt 
(Wetherall et al., 2018). However, the most up to date review on the topic has proposed to 
separately consider neurocognitive predictors of ideation (Boaz Y Saffer & Klonsky, 2018) as 
this would allow to capture a more detailed neuropsychological profile of this particular group. 
A better understanding of cognitive schemas in patients who have suicidal ideation may help 
clinicians to indicate the need for emergency care and early intervention.  
Our study aimed at identifying associations between cognitive functioning and suicidal 
ideation in a sample of patients with AMD, by using specific neurocognitive assessment with 
relevant tests of executive function including impulsive decision-making, executive planning 
and attentional set-shifting. 
Methods 
This cross-sectional study included 186 (age = 39 ± 12.3 years; 142 [76.3 %] females) 
consecutive outpatients with AMD attending the Stress Disorders Clinic in Palanga, Lithuania. 
Socio-demographic and clinical information including diagnosis and suicidal ideation, as 
defined by The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998), 
were collected. The Hamilton 14-item Anxiety (HAM-A) and 17-item Depression (HAM-D) 
Rating Scales were used to evaluate symptoms of anxiety and depression (Hamilton, 1959, 
1960; Zimmerman et al., 2013). In this study population, the HAM-A (Cronbach’s α = .900) 
and HAM-D (Cronbach’s α = .833) had shown a good internal reliability. Psychomotor 
performance and incidental learning were assessed using the Digit Symbol Test (Wechsler, 
1981). Trail Making Tests A and B respectively measured perceptual speed, task-switching 
and executive control (Strauss, Sherman, & Spreen, 2006).  
Additionally, 21 consecutive patient with AMD completed tests from the Cambridge 
Automated Neuropsychological Test Battery CANTAB® (CANTAB®, 2018) including tests 
of set-shifting (Interdimensional/extradimensional set-shift tasks [ID/ED]), executive planning 
(Stockings of Cambridge [SOC]), and decision making (Cambridge Gamble Task [CGT]). 
Non-completers did not differ significantly from completers in socio-demographic 
characteristics, medication use, and depressive/anxiety symptom severity (all p’s > .05).  
Two-tailed Student’s t-test, Fisher’s χ2 or Mann-Whitney U tests were applied to compare 
socio-demographic, clinical, anxiety, depression as well as cognitive function characteristics 
in AMD patients with and without suicidal ideation. We used Benjamini-Hochberg adjustment 
for multiple comparisons in the cognitive function domain, setting a critical value for a false 
discovery rate of .10. 
Next, we sought to investigate if discovered differences in cognitive functioning testing results, 
as a function of suicidal ideation, were independent from socio-demographic characteristics, 
medication use, and depressive/anxiety symptom severity. We employed multivariable 
regression analysis with a specific cognitive domain as the dependent variable and the presence 
of suicidal ideation as an independent factor adjusting for age (in years), gender (men [1] or 
women [2]), education status (up to 8 years [1], high school [2] or college/university degree 
[3]), other currently used medications, such as antidepressants, tranquilizers, mood stabilizers 
and neuroleptics (use [1] or non-use [0]), and depressive (HAM-D score) and anxiety symptom 
severity (HAM-A score). All statistical analyses were conducted using the SPSS 17.0 for 
Windows. 
Results 
A total of 186 patients were included in the final analysis. In this sample group, approximately 
21.5% (n = 40) patients had been diagnosed with one mood disorder, 28.5% (n = 53) had been 
diagnosed with one anxiety disorder, and 50.0% (n = 93) patients had been diagnosed with 
AMD. Almost half of patients included (45.7%, n = 85) had suicidal ideations (Table 1). Scores 
on the CGT overall proportion bet and the CGT risk taking test were found to be significantly 
higher among patients with suicidal ideation as compared to patients without suicidal ideation 
(.57[.51–.70] vs. .46[.41–.51], U = 17.0, p = .007; .65[.55–.75] vs. .51[.49–.54], U = 12.0, p = 
.002). There were no other significant differences for neurocognitive test scores among those 
with and without suicidal ideation (all p’s > .05).  
Next we evaluated if performance on the CGT overall proportion bet and the CGT risk taking 
as function of suicidal ideation were independent from evaluated socio-demographic 
characteristics, medication use, and depressive/anxiety symptoms. Furthermore, in a 
multivariable regression analysis, suicidal ideation was associated with greater overall 
proportion bet and risk taking on the CGT task ( = .726, p = .010 and  = .634, p = .019) after 




Our study results confirmed previous findings that suicidal ideation is associated with impaired 
cognitive performance and poor decision-making (Marzuk, Hartwell, Leon, & Portera, 2005; 
Onat et al., 2018; B. Y. Saffer & Klonsky, 2017; Westheide et al., 2008).  
Neurocognitive functions have received little consideration in the suicide risk assessment of 
patients with AMD. A neurocognitive model of suicidal behaviour suggests that the alteration 
of specific cognitive functions may facilitate the development of a suicidal crisis during 
stressful circumstances, independently of psychiatric comorbidity (Richard-Devantoy, Ding, 
Lepage, Turecki, & Jollant, 2016).  
In this study, markers of impulsive decision making, but not of executive planning or set-
shifting, differentiated those with suicidal ideation, which is reflective of previous research 
findings in psychiatric samples (Gvion & Apter, 2011). However, we did not observe any 
differences between groups in other areas of neurocognitive functioning.  
A recent meta-analysis by Richard-Devantoy and colleagues claim that even though TMT is 
adequate and widely used as a test to measure cognitive deficits in psychiatric patients with 
suicidal ideation, TMT is still more closely related to symptoms of mood disorders than to 
suicidal behaviour (Richard-Devantoy et al., 2016). This may explain our study results of non-
significant relationship between TMT and suicidal ideation. A recent review has pointed out 
that ideators differed most from non-suicidal individuals on measures of processing speed, 
global executive functions, and global cognitive function (Boaz Y Saffer & Klonsky, 2018). 
Given the fact that we used MINI to identify ideators we had a lack of information about 
frequency and severity of suicide ideation. We could expect that mild and severe forms of 
ideation might influence differently neurocognitive function. In addition to this, cross-sectional 
nature of the study precludes us from making causal implications. Without knowing the 
temporal sequence of events, it is only a hypothesis whether neurocognitive differences pre-
cede suicide ideation. For example, a large prospective study of U.S. soldiers found that global 
cognitive function impairment predicted suicide ideation (Naifeh et al., 2017). Thus, future 
studies should longitudinally assess cognitive predictors of ideation and suicide ideation 
frequency and severity to obtain more detailed profile of neurocognitive function of those with 
suicidal ideation.  
Cognitive deficits may constitute relevant intervention targets for identifying or treating 
suicidality. Our results suggest that testing for neurocognitive biomarkers of suicide ideation 
risk may complement clinical assessment in patients with AMD.  
The strengths of our study include well-validated scales, as well as modern instruments for 
measuring neurocognitive markers. Although this research was carefully prepared, there are 
several limitations to be considered when interpreting results. First, there was a lack of 
prospective observation and a relatively small sample size. Second, the generalizability of these 
results may be limited as this study was conducted in a small sample of AMD patients at a 
single unit. 
Conclusion 
Our study indicates that AMD patients with suicidal ideation could be distinguished by the 
presence of cognitive deficits in the executive function domain, particularly in impulse-control 
and risk taking. Cognitive deficits are important therapeutic targets and may allow clinicians 
to evaluate the potential of the CANTAB to serve as a cognitive biomarker of the suicide 
ideation risk in patients with AMD. Further longitudinal studies examining other cognitive 
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Age, mean± SD   38.9  12.3 40.1  11.0 37.5  13.6 .169 
Gender, n (%)     
Men 44 (23.7) 25 (24.8) 19 (22.4) .732 
Women 142 (76.3) 76 (75.2) 66 (77.6)  
Education, n (%)     
Secondary 65 (34.9) 31 (30.7) 34(40.0) .394 
College 23 (12.4) 14 (13.9) 9(10.6)  
University 98 (52.7) 56 (55.4) 42 (49.4)  
Diagnosis, n (%)     
Major depression disorder  40 (21.5) 21 (20.8) 19 (22.4) <.001 
Anxiety disorder 53 (28.5) 41 (40.6) 12 (14.1)  
Mood and anxiety disorder 93 (50.0) 39 (38.6) 54 (63.5)  
Current medication use, n(%)     
Antidepressants 137 (73.7) 68 (67.3) 69 (81.2) .033 
Tranquilizers 76 (40.9) 38 (37.6) 38 (44.7) .328 
Mood stabilizers 7 (3.8) 1 (1.0) 6 (7.1) .030 
Neuroleptics 47 (25.3) 22 (21.8) 25 (29.4) .233 
Obesity (BMI>30 kg/m²), n(%)  28 (15.6) 12 (12.2) 16 (19.8) .169 
History of smoking, n(%)   49 (26.3) 20 (19.8) 29 (34.1) .027 
Depression Hamilton, mean± SD    14.9  7.3 13.1  6.5 17.1  7.7 <.001 
Anxiety Hamilton, mean± SD    24.0  9.9 22.3  9.5 26.2  9.9 .007 
Digit Symbol Test, mean± SD 
Raw score 46.4  10.9 46.7  9.9 46.0  12.0 .709 
Pairs recalled correctly  5.3  2.6 5.3  2.6 5.4  2.5 .660 
Digit Symbol Test time (s) 138.9  38.5 137.2  35.2 140.9  42.3 .518 
Trail Making Test, mean± SD      
Test A Time (s)  29.2  11.0 28.4  9.2 30.3  12.8 .267 
Test B Time (s)  75.1  32.3 76.0  29.7 74.1  35.4 .695 
Cambridge Gambling Task, median (IQR) 
N=21 
    
Deliberation time (ms) 2711 (2217–3157) 2627 (2225–3122) 2743 (2199–3286) .573 
Overall proportion bet .51 (.46–.68) .46 (.41–.51) .57 (.51–.70) .007* 
Quality of decision making .92 (.87–.96) .92 (.74–.96) .92 (.88–.97) .481 
Risk adjustment .73 (–0.02–1.3) .72 (.11–1.4) .73 (–.04–1.1) .526 
Risk taking .55 (.51–.69) .51 (.49–.54) .65 (.55–.75) .002* 
Intradimensional/extradimensional set-shift 
tasks, median (IQR) 
    
Total errors adjusted 14.0(10.0–55.5) 13.5 (8.0–55.8) 17.0 (11.0–56.0) .378 
Stages completed 9.0 (8.0–9.0) 9.0 (7.0–9.0) 9.0 (9.0–9.0) .535 
Stockings of Cambridge Task     
Mean moves 5 moves 6.8 (5.6–8.3) 7.1 (5.8–8.6) 6.8 (5.5–7.5) .396 
 
Student’s t or Mann-Whitney U test was used for continuous variables and the χ2 test or Fisher’s Exact test for categorical 
variables. 
 
* Statistically significant (significance of p values in cognitive functioning domains are adjusted to Benjamini-Hochberg 
correction for multiple comparisons) 0.10. 
